Compare · ATRC vs RMD
ATRC vs RMD
Side-by-side comparison of AtriCure Inc. (ATRC) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ATRC and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $34.07B, about 11.6x ATRC ($2.94B).
- Over the past year, ATRC is up 51.1% and RMD is down 10.8% - ATRC leads by 61.9 points.
- RMD has been more active in the news (9 items in the past 4 weeks vs 2 for ATRC).
- RMD has more recent analyst coverage (25 ratings vs 14 for ATRC).
- Company
- AtriCure Inc.
- ResMed Inc.
- Price
- $56.12-2.84%
- $239.08-1.35%
- Market cap
- $2.94B
- $34.07B
- 1M return
- -5.01%
- +4.60%
- 1Y return
- +51.06%
- -10.84%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2005
- News (4w)
- 2
- 9
- Recent ratings
- 14
- 25
AtriCure Inc.
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States, Europe, Asia, and internationally. It offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. The company also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used to treat symptomatic persistent and long-standing persistent atrial fibrillation patients; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, it sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; COBRA Fusion Surgical Ablation System; Fusion Magnetic Retriever System; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. The company markets and sells its products through independent distributors and direct sales personnel. AtriCure, Inc. was incorporated in 2000 and is headquartered in Mason, Ohio.
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest ATRC
- AtriCure to Announce Third Quarter 2026 Financial Results
- Chief Technical Officer Privitera Salvatore sold $271,140 worth of shares (4,519 units at $60.00) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 142,745 units (SEC Form 4)
- Director Groves Regina E sold $288,071 worth of shares (5,313 units at $54.22), decreasing direct ownership by 13% to 34,546 units (SEC Form 4)
- Chief Technical Officer Privitera Salvatore sold $201,135 worth of shares (3,657 units at $55.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 147,264 units (SEC Form 4)
- Bloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600
- Chief Technical Officer Privitera Salvatore sold $407,558 worth of shares (7,763 units at $52.50) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 150,921 units (SEC Form 4)
- Chief Legal Officer Dahlquist Karl S. sold $458,099 worth of shares (9,370 units at $48.89), decreasing direct ownership by 10% to 87,319 units (SEC Form 4)
- AtriCure to Participate in the 2026 Wells Fargo Health Care Conference
- Amendment: SEC Form SCHEDULE 13G/A filed by AtriCure Inc.
- Director Prange Karen sold $138,283 worth of shares (3,564 units at $38.80), decreasing direct ownership by 14% to 22,809 units (SEC Form 4)
Latest RMD
- SEC Form 4 filed by ResMed Inc.
- SEC Form DEFA14A filed by ResMed Inc.
- SEC Form DEF 14A filed by ResMed Inc.
- Amendment: SEC Form 4 filed by Chairman and CEO Farrell Michael J.
- Chief Product Officer Leong Justin was granted 6,461 units of ResMed Common Stock, increasing direct ownership by 22% to 35,489 units (SEC Form 4)
- Global General Counsel Rider Michael J was granted 3,230 units of ResMed Common Stock, increasing direct ownership by 34% to 12,718 units (SEC Form 4)
- Chairman and CEO Farrell Michael J. was granted 13,547 units of ResMed Common Stock, increasing direct ownership by 3% to 479,803 units (SEC Form 4)
- Chief Financial Officer Bloomer Aaron was granted 9,072 units of ResMed Common Stock (SEC Form 4)
- Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
- ResMed upgraded by RBC Capital Mkts with a new price target